-
公开(公告)号:KR101174494B1
公开(公告)日:2012-08-22
申请号:KR1020090134751
申请日:2009-12-30
Applicant: 대한민국(농촌진흥청장)
IPC: C07K14/535 , C12N15/27 , C12N15/63 , A61K38/18
Abstract: 본발명은인간과립구콜로니자극인자의생물학적활성증가변이체에관한것으로서, 더욱상세하게는생리활성단백질의체내혈액중의안정성및 활성을증가시키기위해인간과립구콜로니자극인자의특정부위에 Asn-X-Ser/Thr (N-X-S/T) 서열이하나이상형성되어이 부위에서당쇄화가일어나도록아미노산이변형된인간과립구콜로니자극인자(G-CSF)의변이체및 당쇄화된인간과립구콜로니자극인자에관한것이다.
-
公开(公告)号:KR1020110078038A
公开(公告)日:2011-07-07
申请号:KR1020090134751
申请日:2009-12-30
Applicant: 대한민국(농촌진흥청장)
IPC: C07K14/535 , C12N15/27 , C12N15/63 , A61K38/18
Abstract: PURPOSE: A mutant human G-CSF with increased biological activity is provided to ensure superior biological activity and excellent economic effect with low dosage. CONSTITUTION: A mutant human G-CSF has amino acid modification by N-glycosylateion by formation of Asn-X-Ser/Thr(N-X-S/T) sequence in an amino acid residues: T1-P10 (T1-P-L-Q-P-A-S-S-L-P10); K40-Q70 (K40-L-C-H-P-E-E-L-V-L-L-G-H-S-L-G-I-P-W-A-P-L-S-S-C-P-S-Q-A-L-Q70); or L124-S142 (L124-G-M-A-P-A-L-Q-P-T-Q-G-A-M-P-A-F-A-S142). A pharmaceutical composition contains the mutant human G-CSF.
Abstract translation: 目的:提供具有增加生物活性的突变型人类G-CSF,以确保优异的生物活性和低剂量的优异的经济效果。 构成:突变型人G-CSF通过在氨基酸残基:T1-P10(T1-P-L-Q-P-A-S-S-L-P10)中形成Asn-X-Ser / Thr(N-X-S / T)序列而进行N-糖基化的氨基酸修饰。 K40-Q70(K40-L-C-H-P-E-E-L-V-L-L-G-H-S-L-G-I-P-W-A-P-L-S-S-C-P-S-Q-A-L-Q70) 或L124-S142(L124-G-M-A-P-A-L-Q-P-T-Q-G-A-M-P-A-F-A-S142)。 药物组合物含有突变型人G-CSF。
-